A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM15211
| Status: | Recruiting |
|---|---|
| Conditions: | Obesity Weight Loss |
| Therapuetic Areas: | Endocrinology |
| Healthy: | No |
| Age Range: | 18 - 65 |
| Updated: | 5/3/2018 |
| Start Date: | April 4, 2018 |
| End Date: | October 2018 |
A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single Ascending Dose of HM15211 in Healthy Obese Subjects
Single ascending dose of HM15211 in healthy obese subjects.
A First-in-human study to evaluate the safety, tolerability, pharmacokinetics and
pharmacodynamics after single ascending dose of HM15211 in healthy obese subjects.
pharmacodynamics after single ascending dose of HM15211 in healthy obese subjects.
Inclusion Criteria:
- Female subjects must be non-pregnant and non-lactating
Exclusion Criteria:
- Participation in an investigational study within 30 days prior to dosing
We found this trial at
1
site
Click here to add this to my saved trials
